A new cell line (SKS) established from ascites of a patient with neuroendocrine small cell carcinoma of the uterine cervix had a good tumorigenicity and caused marked peritoneal dissemination, and was also highly sensitive to gemcitabine in an in vitro chemosensitivity test. SKS cells were small round cells with a high nuclear/cytoplasmic (N/C) ratio and grew into colony-like aggregates, forming spherical aggregates of floating cells. The population doubling time was 44 h. The number of chromosomes ranged from 50 to 56. On examination of the ultrastructure, membrane-bound dense-core neurosecretory-type granules were observed in the cytoplasm. Neuron-specific enolase (NSE) was immunocytochemically positive in the cytoplasm, and 9.3 ng/ml of NSE was detected in the cell culture supernatant. Human papillomavirus was not detected. In the p53 gene, a 3-bp deletion, AAC (Asn), was detected at codon 131 in exon 5. SKS exhibited good tumorigenicity, and the tumor doubling time was 11 days. Intraperitoneal injection of the cells caused peritoneal dissemination, and marked ascites formation was observed. SKS was highly sensitive to gemcitabine, and the 50% growth inhibitory concentration was 30 nM. SKS cells are useful as a model of neuroendocrine small cell carcinoma of the cervix, and chemotherapy using gemcitabine may possibly be effective in this malignancy.

Keywords:
Neuroendocrine small cell carcinoma, Uterine cervix, Cell line, Tumorigenicity, Dissemination, Chemosensitivity, Gemcitabine
1.
Sheets EE, Berman ML, Hrountas CK, Liao SY, DiSaia PJ: Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol 1988;71:10–14.
2.
Randall ME, Kim JA, Mills SE, Hahn SS, Constable WC: Uncommon variants of cervical carcinoma treated with radical irradiation. A clinicopathologic study of 66 cases. Cancer 1986;57:816–822.
3.
Sevin BU, Method MW, Nadji M, Lu Y, Averette HA: Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer 1996;77:1489–1493.
4.
van Nagell JR, Powell DE, Gallion HH, Elliott DG, Donaldson ES, Carpenter AE, Higgins RV, Kryscio R, Pavlik EJ: Small cell carcinoma of the uterine cervix. Cancer 1988;62:1586–1593.
5.
Abeler VM, Holm R, Nesland JM, Kjorstad KE: Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer 1994;73:672–677.
6.
Seabright M: A rapid banding technique for human chromosomes. Lancet 1971;ii:971–972.
7.
Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874–879.
8.
Ichimura H, Yamasaki M, Tamura I, Katsumoto T, Sawada M, Kurimura O, Furuyama J, Kurimura T: Establishment and characterization of a new cell line TC-YIK originating from argyrophil small cell carcinoma of the uterine cervix integrating HPV16 DNA. Cancer 1991;67:2327–2332.
9.
Ku JL, Kim WH, Park HS, Kang SB, Park JG: Establishment and characterization of 12 uterine cervical-carcinoma cell lines: Common sequence variation in the E7 gene of HPV-16-positive cell lines. Int J Cancer 1997;72:313–320.
10.
Ohtake H, Katabuchi H, Tashiro H, Khan S, Fukumatsu Y, Okamura H: Establishment of a new cell line, OKT1, from small cell carcinoma secreting ectopic ACTH of the uterine cervix. Gynecol Oncol 1998;71:177–184.
11.
Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH: Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 1998;83:712–718.
12.
Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ: Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328–337.
13.
Pao CC, Lin CY, Chang YL, Tseng CJ, Hsueh S: Human papillomaviruses and small cell carcinoma of the uterine cervix. Gynecol Oncol 1991;43:206–210.
14.
Stoler MH, Mills SE, Gersell DJ, Walker AN: Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991;15:28–32.
15.
Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
16.
D’Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339–346.
17.
Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CH, Terada M, Koeffler HP: p53 mutations in human lung tumors. Cancer Res 1992;52:1695–1698.
18.
Sameshima Y, Matsuno Y, Hirohashi S, Shimosato Y, Mizoguchi H, Sugimura T, Terada M, Yokota J: Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 1992;7:451–457.
19.
Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP: Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 1993;72:1272–1280.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.